Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month
- 15 minutes ago
- 1 min read
He discusses learnings from the company's previous data release in early June and how he believes the new data presented gives investors a fuller picture of the efficacy and safety profile of the therapy. He discusses next steps from a regulatory and business standpoint, clarifies a key point of investor confusion, and also provides an update on the company's Crohn's trial.
.png){kind=logo}